International Agency for Research on Cancer (IARC) - Summaries & Evaluations

(Group 3)

For definition of Groups, see Preamble Evaluation.

VOL.: 50 (1990) (p. 115)

CAS No.: 29069-24-7
Chem. Abstr. Name: Pregna-1,4-diene-3,20-dione, 21-(4-{4-[bis(2-chloroethyl)amino]phenyl}-1-oxybutoxy)-11,17-dihydroxy-(11b)-

5. Summary of Data Reported and Evaluation

5.1 Exposure data

Prednimustine has been used as a cytostatic drug, mainly for the treatment of malignancies of lymphatic tissue.

5.2 Experimental carcinogenicity data

Prednimustine given by oral administration to rats induced a low but significant increase in the incidence of squamous-cell carcinomas of the external auditory canal.

5.3 Human carcinogenicity data

No data were available to the Working Group.

5.4 Other relevant data

In humans, prednimustine causes leukopenia and thrombocytopenia; in experimental animals, it causes lymphopenia. It is hydrolysed to chlorambucil and prednisolone in vivo.

5.5 Evaluation

There is inadequate evidence for the carcinogenicity of prednimustine in experimental animals.

No data were available from studies in humans on the carcinogenicity of prednimustine.

Overall evaluation

Prednimustine is not classifiable as to its carcinogenicity to humans (Group 3).

For definition of the italicized terms, see Preamble Evaluation.


Last updated: 11 November 1997

    See Also:
       Toxicological Abbreviations